Atrys Health SA (ATRY) AI Stock Analysis

• Market Cap: €241.61M
• Dividend Yield: N/A
• Average Volume (3M): 83.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: 15.90%
• EPS Growth: 37.03%
• Country: ES
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 76,014,190
• 10 Day Avg. Volume: 190,561
• 30 Day Avg. Volume: 83,732
• PEG Ratio: 0.27
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 1.20
• P/FCF Ratio: -25.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €5.00
• Price Target Upside: 85.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: €2.50 ▼(-7.41% Downside)

Atrys Health SA's overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant profitability and liquidity challenges, with bearish technical indicators further weighing on the score. Valuation metrics also suggest the stock is overvalued given its current earnings potential.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability.

Gross Profit Margin

A strong gross profit margin reflects efficient cost management and pricing power, contributing to potential future profitability.

Moderate Leverage

Moderate leverage provides financial flexibility and reduces risk, supporting long-term operational stability in the biotechnology industry.

Negative Factors

Profitability Challenges

Negative profitability metrics indicate operational inefficiencies and challenges in achieving sustainable earnings, impacting long-term viability.

Liquidity Challenges

Negative free cash flow suggests insufficient cash generation to cover capital needs, potentially limiting growth and investment opportunities.

Increasing Liabilities

Increasing liabilities relative to assets can strain financial health, reducing the company's ability to withstand economic downturns.

Atrys Health SA Business Overview & Revenue Model

Company Description

Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.

How the Company Makes Money

Atrys Health generates revenue through multiple streams, primarily from its telemedicine and diagnostic imaging services. The company charges healthcare providers and patients for the use of its telehealth platform, which allows for remote consultations and diagnostic services. Additionally, Atrys partners with hospitals and clinics to provide specialized oncology services, where revenue is generated through service fees and contracts. The company may also benefit from collaborations with pharmaceutical firms for clinical trials and research initiatives, further diversifying its income sources. Key partnerships with healthcare institutions enhance its market reach and contribute significantly to its earnings.

Atrys Health SA Financial Statement Overview

Summary

Atrys Health SA shows strong revenue growth but faces significant profitability and liquidity challenges. The balance sheet indicates increasing leverage, and cash flow improvements are insufficient to meet capital expenditure demands.

Income Statement

Atrys Health SA has shown consistent revenue growth, with a 5.55% increase from 2023 to 2024. However, profitability metrics are concerning with a negative EBIT and net income indicating ongoing operational challenges. The gross profit margin remains strong at 68.36% for 2024, but the net profit margin is negative due to substantial net losses.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.66 in 2024, reflecting reasonable leverage for the biotechnology industry. However, a declining equity ratio from 46.06% in 2023 to 43.32% in 2024 indicates increasing liabilities relative to assets. Return on equity is negative, highlighting profitability issues.

Cash Flow

Operating cash flow has improved to a positive $2.997 million in 2024, but free cash flow remains negative, indicating ongoing capital expenditure demands. The operating cash flow to net income ratio is not meaningful due to negative net income, and free cash flow growth remains negative, pointing to liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	227.00M	212.74M	201.57M	158.37M	121.01M	33.81M
Gross Profit	59.30M	145.38M	141.77M	24.20M	100.89M	12.40M
EBITDA	27.67M	19.07M	31.91M	16.63M	5.87M	6.68M
Net Income	-24.59M	-31.77M	-45.59M	-23.15M	-23.20M	-5.55M
Balance Sheet
Total Assets	579.13M	584.19M	629.00M	705.28M	565.63M	175.78M
Cash, Cash Equivalents and Short-Term Investments	20.58M	29.29M	42.18M	35.84M	41.70M	17.60M
Total Debt	193.40M	166.13M	254.00M	241.22M	154.95M	71.46M
Total Liabilities	337.61M	330.95M	339.12M	367.71M	291.65M	100.45M
Stockholders Equity	241.49M	253.10M	289.87M	337.63M	274.03M	71.38M
Cash Flow
Free Cash Flow	17.80M	-10.14M	-547.00K	-30.59M	-3.87M	-6.69M
Operating Cash Flow	23.28M	3.00M	5.70M	-15.43M	4.69M	-1.40M
Investing Cash Flow	-11.95M	-12.95M	395.00K	-80.59M	-2.45M	-52.08M
Financing Cash Flow	-18.90M	-11.51M	8.19M	94.77M	14.08M	62.63M

Atrys Health SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ATRY, the sentiment is Negative. The current price of 2.7 is below the 20-day moving average (MA) of 2.81, below the 50-day MA of 3.01, and below the 200-day MA of 2.93, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 36.94 is Neutral, neither overbought nor oversold. The STOCH value of 38.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:ATRY.

Atrys Health SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRM	73 Outperform	€227.12M	―	―	3.29%	―	―
RJF	65 Neutral	€221.33M	49.72	2.03%	1.82%	-1.19%	-54.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORY	48 Neutral	€272.44M	-52.51	-2.87%	―	―	36.23%
ATRY	42 Neutral	€241.61M	-9.82	-9.43%	―	15.90%	37.03%